MA54296A - Procédés de traitement du métabolisme lipidique dérégulé - Google Patents

Procédés de traitement du métabolisme lipidique dérégulé

Info

Publication number
MA54296A
MA54296A MA054296A MA54296A MA54296A MA 54296 A MA54296 A MA 54296A MA 054296 A MA054296 A MA 054296A MA 54296 A MA54296 A MA 54296A MA 54296 A MA54296 A MA 54296A
Authority
MA
Morocco
Prior art keywords
treating
methods
lipid metabolism
disregulated
disregulated lipid
Prior art date
Application number
MA054296A
Other languages
English (en)
Inventor
Giuseppe Astarita
Paolo Gilbert Di
kai lin Lin
Kathryn M Monroe
Alicia A Nugent
Lengerich Bettina Van
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MA54296A publication Critical patent/MA54296A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054296A 2018-11-26 2019-11-26 Procédés de traitement du métabolisme lipidique dérégulé MA54296A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771456P 2018-11-26 2018-11-26
US201962817955P 2019-03-13 2019-03-13
US201962890506P 2019-08-22 2019-08-22

Publications (1)

Publication Number Publication Date
MA54296A true MA54296A (fr) 2021-10-06

Family

ID=68988303

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054296A MA54296A (fr) 2018-11-26 2019-11-26 Procédés de traitement du métabolisme lipidique dérégulé

Country Status (7)

Country Link
US (1) US20230132366A9 (fr)
EP (1) EP3887401A2 (fr)
JP (1) JP7607559B2 (fr)
CN (1) CN113302206A (fr)
CA (1) CA3120970A1 (fr)
MA (1) MA54296A (fr)
WO (1) WO2020112889A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
SG11202105276TA (en) 2018-12-03 2021-06-29 Univ Texas Oligo-benzamide analogs and their use in cancer treatment
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN113614110B (zh) 2019-02-20 2025-03-25 戴纳立制药公司 抗trem2抗体及其使用方法
WO2021146256A1 (fr) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anticorps anti-trem2 et leurs procédés d'utilisation
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
AU2021289144A1 (en) * 2020-06-11 2022-12-15 King's College London TREM2 chimeric receptor
TW202218683A (zh) * 2020-08-05 2022-05-16 美商維佳神經科學有限公司 使用trem2促效劑治療與群落刺激因子1受體功能障礙相關之疾病
CN115015412B (zh) * 2022-05-26 2024-07-05 江苏独步生物科技有限公司 一种与中枢神经损伤修复相关的分子靶标及其应用
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025064933A1 (fr) * 2023-09-22 2025-03-27 The Trustees Of Columbia University In The City Of New York Restauration de tim4 dans des macrophages hépatiques pour traiter la stéatohépatite non alcoolique (nash)
CN117771226B (zh) * 2023-12-28 2024-08-20 山东博森医学工程技术有限公司 一种加快骨关节炎损伤修复的促进剂
WO2025194147A1 (fr) * 2024-03-15 2025-09-18 The Children's Medical Center Corporation Modulation thérapeutique de trem2 et ses utilisations contre la dégénérescence rétinienne
CN118983095A (zh) * 2024-08-01 2024-11-19 中国人民解放军总医院第五医学中心 脂质在hiv感染者抗逆转录病毒治疗后免疫重建结果预测中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR14523E (fr) 1911-02-06 1911-12-30 Daniel German Caswell Perfectionnements dans les vélocipèdes
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
DE3202100A1 (de) 1982-01-23 1983-08-04 Basf Ag, 6700 Ludwigshafen Substituierte benzoesaeure-4-hydroxyanilide, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE69224660C5 (de) 1991-12-18 2010-06-02 The Salk Institute For Biological Studies, La Jolla Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ATE195716T1 (de) 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
CA2153236A1 (fr) 1993-01-11 1995-02-09 Marcus F. Boehm Composes selectifs pour les recepteurs de la retinoide x; moyens permettant la modulation de procedes via ces recepteurs
CA2153235C (fr) 1993-01-11 2005-08-23 Marcus F. Boehm Composes selectifs pour les recepteurs de la retinoide x; moyens permettant la modulation de procedes via ces recepteurs
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
CA2160135A1 (fr) 1993-04-07 1994-10-13 Donald P. Mcdonnell Methode pour depister les agonistes de recepteurs
PL180048B1 (en) 1994-08-10 2000-12-29 Fhoffmann La Roche Ag Ligands of retinic acid x-receptors
US5721103A (en) 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
JP4001913B2 (ja) 1994-12-30 2007-10-31 リガンド・ファーマシューティカルズ・インコーポレイテッド 新規なトリエンレチノイド化合物および方法
JPH09330101A (ja) 1996-06-13 1997-12-22 Kokusai Chodendo Sangyo Gijutsu Kenkyu Center 制御装置及び方法
IT1286031B1 (it) 1996-10-24 1998-07-07 Enichem Spa Procedimento per la produzione di polimeri vinilaromatici ad elevato grado di sindiotassia
US6969711B2 (en) 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
CA2392568A1 (fr) 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose
US20030086923A1 (en) 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2471311A1 (fr) 2001-12-21 2003-07-24 Pharmacia Corporation Modulateurs du recepteur x du foie de thioether aromatique
US20050123580A1 (en) 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
AU2003233670A1 (en) 2002-05-24 2003-12-12 Pharmacia Corporation Sulfone liver x-receptor modulators
AU2003241601A1 (en) 2002-05-24 2003-12-12 Pharmacia Corporation Anilino liver x-receptor modulators
JP2005539081A (ja) 2002-09-17 2005-12-22 ファルマシア コーポレイション 芳香族肝臓ｘ受容体モジュレーター
WO2004058175A2 (fr) 2002-12-23 2004-07-15 Irm Llc Nouvelle utilisation d'agonistes des recepteurs hepatiques x
US20050009837A1 (en) 2003-05-20 2005-01-13 City Of Hope Modulators of lipid metabolism and methods of use
JP2005128010A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd インスリン抵抗性改善剤のスクリーニング方法
EP2284157A1 (fr) 2003-12-12 2011-02-16 Wyeth Quinolines utiles au traitement de maladies cardiovasculaires
US7592363B2 (en) 2004-08-03 2009-09-22 Wyeth Indazoles
CN101547688A (zh) 2006-09-19 2009-09-30 惠氏公司 Lxr激动剂用于治疗骨关节炎的用途
US9149492B2 (en) 2008-10-08 2015-10-06 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease
KR20110117689A (ko) * 2009-01-28 2011-10-27 더 메디컬 리서치, 인프라스트럭쳐, 앤드 헬스 서비시즈 펀드 오브 더 텔 아비브 메디컬 센터 염증성, 자가면역 및 심장혈관 질환의 에오탁신-2(ｃｃｌ24) 억제제
JP5719340B2 (ja) 2009-03-20 2015-05-20 レティーナ インプラント アーゲー 能動型網膜インプラント
US20140235676A1 (en) 2011-10-13 2014-08-21 Case Western Reserve University Rxr agonist compounds and methods
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
WO2015038585A1 (fr) 2013-09-11 2015-03-19 Trustees Of Dartmouth College Méthode permettant d'inhiber de manière sélective acat1 dans le traitement de la maladie d'alzheimer
WO2015061686A2 (fr) 2013-10-25 2015-04-30 St. Jude Children's Research Hospital, Inc. Agonistes du récepteur des rétinoïdes x type gamma et antagonistes du récepteur des rétinoïdes x type alpha utilisés pour le traitement du cancer
US10100308B2 (en) 2014-05-29 2018-10-16 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
US11103489B2 (en) 2015-06-30 2021-08-31 National University Corporation Okayama University Drug for preventing or treating inflammatory bowel disease
WO2017058866A1 (fr) 2015-09-28 2017-04-06 Precision Immune, Inc. Anticorps anti-trem2 et leurs utilisations
SG10201912150TA (en) 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3368160B1 (fr) 2015-10-31 2023-05-17 IO Therapeutics, Inc. Traitement de troubles du système nerveux à l'aide de doses d'hormones thyroïdiennes d'agonistes de rxr
US20190367623A1 (en) * 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
MD3601358T2 (ro) 2017-08-03 2023-10-31 Alector Llc Anticorpi anti-TREM2 și metode de utilizare a acestora
CA3083660A1 (fr) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anticorps anti-trem2 et methodes associees

Also Published As

Publication number Publication date
US20220025039A1 (en) 2022-01-27
WO2020112889A3 (fr) 2020-07-30
JP2022513114A (ja) 2022-02-07
CA3120970A1 (fr) 2020-06-04
WO2020112889A2 (fr) 2020-06-04
EP3887401A2 (fr) 2021-10-06
US20230132366A9 (en) 2023-04-27
JP7607559B2 (ja) 2024-12-27
CN113302206A (zh) 2021-08-24
WO2020112889A9 (fr) 2021-06-10

Similar Documents

Publication Publication Date Title
MA54296A (fr) Procédés de traitement du métabolisme lipidique dérégulé
EP3389672A4 (fr) Compositions et procédés de traitement de maladies hépatiques
EP3288382A4 (fr) Procédés de traitement du cancer
MA47613A (fr) Compositions et procédés de traitement du cancer
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3735325A4 (fr) Compositions et procédés de traitement de surface
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3426250A4 (fr) Procédés de traitement
EP3310174A4 (fr) Procédés et compositions de traitement du cancer du poumon autre que le cancer bronchique à petites cellules
EP3373300A4 (fr) Procédé et appareil de traitement de signal vocal
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3341392A4 (fr) Compositions et procédés de traitement de la douleur
EP3826667A4 (fr) Anticorps contre claudin 6 et procédés de traitement du cancer
EP3389657A4 (fr) Procédés de traitement de l'hyperalgésie
EP3442946A4 (fr) Procédés de traitement du cancer
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
EP3801563A4 (fr) Matériels et procédés de traitement du cancer
MA55087A (fr) Compositions et procédés de traitement de laminopathies
EP3801510A4 (fr) Procédés de traitement de dystrophies musculaires
EP3463461A4 (fr) Procédés de traitement de la myasthénie grave généralisée réfractaire
EP3830196A4 (fr) Compositions et procédés de traitement de surface
EP4017924A4 (fr) Compositions et procédés de traitement de surface
EP3405172A4 (fr) Procédés et compositions pour le traitement du vieillissement cutané
EP3307913A4 (fr) Procédés de diagnostic et de traitement de l'autisme